Brian Cheng
Stock Analyst at JP Morgan
(1.11)
# 3,571
Out of 4,873 analysts
67
Total ratings
35.85%
Success rate
-18.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Neutral | $130 → $129 | $128.25 | +0.58% | 3 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.09 | -20.71% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $25.79 | +58.98% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $40.00 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $53.67 | +6.20% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $9.56 | +35.98% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.18 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $2.25 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $12.84 | +40.19% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $8.23 | +240.22% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $46 | $16.00 | +187.50% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $3.19 | +936.11% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.54 | +290.88% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $8.93 | +168.76% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.50 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.35 | +1,348.44% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.26 | +534.92% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.54 | +29.98% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.40 | +3,435.35% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.86 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.67 | +794.19% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.08 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.38 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $8.17 | +144.95% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $13.40 | +534.33% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.92 | +111.69% | 1 | Aug 3, 2021 |
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $130 → $129
Current: $128.25
Upside: +0.58%
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.09
Upside: -20.71%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $25.79
Upside: +58.98%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $40.00
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $53.67
Upside: +6.20%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $9.56
Upside: +35.98%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.18
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.25
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $12.84
Upside: +40.19%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.23
Upside: +240.22%
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $16.00
Upside: +187.50%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $3.19
Upside: +936.11%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.54
Upside: +290.88%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $8.93
Upside: +168.76%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.50
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.35
Upside: +1,348.44%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.26
Upside: +534.92%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.54
Upside: +29.98%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.40
Upside: +3,435.35%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $2.86
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.67
Upside: +794.19%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.08
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.38
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $8.17
Upside: +144.95%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $13.40
Upside: +534.33%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.92
Upside: +111.69%